Reviroc

N/A

Report date: 2023/05/05 18:02:25

Base Information

Drug NameReviroc
Drug Alias NameT cell replacement therapy TH9402Allodepleted T-cell ImmunotheRapeuticsT cell replacement therapy (Kiadis Pharma)T cell replacement therapy-Kiadis PharmaReviroc +[8] 
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsCXC chemokine receptor antagonists
TargetsCXC chemokine receptor
Therapy Area/IndicationsGraft vs Host DiseaseHematologic NeoplasmsLymphoma, Follicular +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesKiadis Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKiadis Pharma
Active IndicationsN/A
Inactive IndicationsGraft vs Host DiseaseHematologic NeoplasmsLymphoma, Follicular +[4] 

Other Information

ATC CodeN/A
Related LinksN/A